Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Pharmacokinetic–Pharmacodynamic Relationship: Dose to Pharmacological Effect01:28

Pharmacokinetic–Pharmacodynamic Relationship: Dose to Pharmacological Effect

A drug’s dosage and pharmacokinetic properties determine how quickly it acts, how intense its effects are, and how long it lasts. Higher doses increase drug concentration at receptor sites, producing a hyperbolic curve when pharmacologic response is plotted against drug dose. Converting this scale to a log-linear format results in a sigmoidal curve, better representing dose–response relationships.For drugs following a one-compartment model, the pharmacologic response is directly proportional to...
Dosage Regimens: Partial Pharmacokinetic Parameters01:01

Dosage Regimens: Partial Pharmacokinetic Parameters

It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Drug Dosing: Geriatric Patients01:15

Drug Dosing: Geriatric Patients

Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comprehensive Ethnicity Assessment of Ribociclib Pharmacokinetics in Patients With Early and Advanced Breast Cancer.

Clinical therapeutics·2026
Same author

Physiologically-Based Pharmacokinetics of Ribociclib Drug-Drug Interactions and Organ Impairment Pharmacokinetics in Early Breast Cancer.

Pharmaceuticals (Basel, Switzerland)·2026
Same author

Chromosome centromere copy number amplification associated with exceptional response in HER2-positive metastatic breast cancer patients.

Oncogene·2025
Same author

Spontaneous regression of metastatic disease after palliative debulking surgery for heavily pre-treated extraskeletal myxoid chondrosarcoma: A case report.

Rare tumors·2025
Same author

Cis-regulatory and long noncoding RNA alterations in breast cancer - current insights, biomarker utility, and the critical need for functional validation.

Molecular oncology·2025
Same author

Evaluating Causal Effects on Time-to-Event Outcomes in an RCT in Oncology With Treatment Discontinuation.

Biometrical journal. Biometrische Zeitschrift·2025
Same journal

Population Pharmacokinetic Modelling of Dolutegravir: A Narrative Review.

Clinical pharmacokinetics·2026
Same journal

Partial Area Under the Curve: A Revelatory Story in Pharmacokinetics.

Clinical pharmacokinetics·2026
Same journal

Informing Sampling Design for Lung Distribution Studies Using a Pulmonary Population Minimal PBPK Model.

Clinical pharmacokinetics·2026
Same journal

Revisited Pharmacokinetic Profiles of Methylprednisolone in Plasma and Urine After Single and Multiple Oral Administrations: Relevance in Sports Drug Testing.

Clinical pharmacokinetics·2026
Same journal

ALBI Grade is a Determinant of Lenvatinib Pharmacokinetics, Efficacy, and Toxicities in Japanese Patients with Hepatocellular Carcinoma.

Clinical pharmacokinetics·2026
Same journal

Population Pharmacokinetics of Intravenous Vitamin C in Adults with Sepsis: A Sub-study of the LOVIT Trial.

Clinical pharmacokinetics·2026
See all related articles

Related Experiment Video

Updated: Jun 24, 2026

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration
11:13

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration

Published on: June 9, 2023

Quantitative Pharmacology Justifying Ribociclib Dose in Early Breast Cancer.

Yan Ji1, Craig Wang2, Francois Pierre Combes3

  • 1Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA. yan.ji@novartis.com.

Clinical Pharmacokinetics
|June 23, 2026
PubMed
Summary
This summary is machine-generated.

This study confirms the 400-mg dose of ribociclib is appropriate for early breast cancer (EBC) by analyzing pharmacokinetics and QTcF interval. The lower dose showed reduced side effects compared to advanced breast cancer treatment.

Related Experiment Videos

Last Updated: Jun 24, 2026

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration
11:13

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration

Published on: June 9, 2023

Area of Science:

  • Pharmacology
  • Oncology
  • Clinical Pharmacology

Background:

  • Ribociclib is approved for hormone receptor-positive/human epidermal growth factor receptor 2-negative early breast cancer (EBC) at 400 mg daily.
  • Previously approved for advanced breast cancer at 600 mg daily.
  • Understanding ribociclib pharmacokinetics and QTcF relationship in EBC is crucial for dose justification.

Purpose of the Study:

  • Characterize ribociclib pharmacokinetics in EBC patients.
  • Assess the relationship between ribociclib exposure and QTcF interval.
  • Justify the 400-mg dose for EBC based on safety and efficacy data.

Main Methods:

  • Analysis of data from EBC (pivotal phase III) and advanced breast cancer (phase I-III) trials.
  • Pharmacokinetic analysis using non-compartmental and population methods.
  • Exposure-QTcF relationship assessed via linear mixed-effects modeling.

Main Results:

  • EBC patients at 400 mg showed ~20% higher clearance and ~50% lower exposure than advanced cancer patients at 600 mg.
  • Population was a significant covariate for QTcF response.
  • Lower mean QTcF change from baseline in EBC (10.0 ms) vs. advanced breast cancer (20.7-23.7 ms).
  • EBC patients on 400 mg experienced less neutropenia and QTcF prolongation.

Conclusions:

  • Integrative analysis supports the 400-mg dose of ribociclib for EBC.
  • Revealed population effects on ribociclib pharmacokinetics and QTcF response.
  • Demonstrates the value of quantitative pharmacology in dose justification for oncology drugs.